Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCC IM Cannabis	$2.71 +44.9%	$1.61	$1.29 ▼ $4.49	$6.05M	1.1	49,568 shs	3.15 million shs
MBIO Mustang Bio	$1.28 -0.8%	$1.25	$1.01 ▼ $65.00	$5.60M	2.27	333,377 shs	45,455 shs
SXTC China SXT Pharmaceuticals	$1.52 +0.7%	$2.10	$0.95 ▼ $11.92	$23.90M	1.24	1.14 million shs	65,135 shs
TCRT Alaunos Therapeutics	$2.48 -6.1%	$2.55	$1.31 ▼ $11.50	$4.07M	-1.08	136,341 shs	10,046 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCC IM Cannabis	+44.92%	+58.57%	+83.11%	+28.50%	-25.65%
MBIO Mustang Bio	-0.78%	+7.56%	+10.34%	-53.28%	-86.42%
SXTC China SXT Pharmaceuticals	+0.66%	-8.43%	-37.45%	-66.22%	-82.08%
TCRT Alaunos Therapeutics	-6.06%	-2.36%	+1.22%	+55.00%	-77.04%

Compare MarketRank™

Company	Overall Score	Short Interest Score	News and Social Media Sentiment	Earnings & Valuation
IMCC IM Cannabis	0.8396 of 5 stars	5.0	2.0	0.6
MBIO Mustang Bio	0.8888 of 5 stars	5.0	2.2	0.6
SXTC China SXT Pharmaceuticals	1.4623 of 5 stars	5.0	4.1	0.6
TCRT Alaunos Therapeutics	0.3764 of 5 stars	3.0	1.9	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMCC IM Cannabis	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMCC IM Cannabis	$54.47M	0.11	N/A	N/A	$4.55 per share	0.60
MBIO Mustang Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
SXTC China SXT Pharmaceuticals	$1.82M	13.23	N/A	N/A	$30.46 per share	0.05
TCRT Alaunos Therapeutics	$11K	369.75	N/A	N/A	$3.93 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMCC IM Cannabis	-$7.04M	-$0.64	N/A	N/A	N/A	-25.55%	-129.86%	-23.63%	8/12/2025 (Estimated)
MBIO Mustang Bio	-$51.60M	-$78.00	N/A	N/A	N/A	N/A	N/A	-172.89%	8/12/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	-$35.14M	N/A	0.00	∞	N/A	N/A	-267.77%	-209.18%	8/12/2025 (Estimated)

Latest SXTC, TCRT, IMCC, and MBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IMCC IM Cannabis	-$0.2540	$0.06	+$0.3140	$0.06	$11.45 million	$8.69 million
5/15/2025	Q1 2025	TCRT Alaunos Therapeutics	-$4.50	-$0.67	+$3.83	-$0.67	N/A	$0.00 million
5/14/2025	Q1 2025	MBIO Mustang Bio	N/A	-$0.05	N/A	-$0.05	N/A	N/A
3/31/2025	Q4 2024	IMCC IM Cannabis	-$0.39	-$0.23	+$0.16	-$0.23	$14.48 million	$9.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMCC IM Cannabis	0.10	0.70	0.59
MBIO Mustang Bio	N/A	0.40	0.40
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	4.30	4.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMCC IM Cannabis	7.68%
MBIO Mustang Bio	9.95%
SXTC China SXT Pharmaceuticals	5.02%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
IMCC IM Cannabis	5.91%
MBIO Mustang Bio	0.21%
SXTC China SXT Pharmaceuticals	3.95%
TCRT Alaunos Therapeutics	5.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMCC IM Cannabis	340	2.23 million	2.10 million	Not Optionable
MBIO Mustang Bio	100	4.38 million	952,000	Not Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.52 million	No Data

SXTC, TCRT, IMCC, and MBIO Headlines

Recent News About These Companies

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.com

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

May 16, 2024 | investorplace.com

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

April 12, 2024 | seekingalpha.com

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

April 8, 2024 | investorplace.com

Biora Therapeutics announces $6M registered direct offering and concurrent private placement

April 1, 2024 | msn.com

Sharp increase in TCRT’s short interest leads to surge in days-to-cover ratio

February 1, 2024 | knoxdaily.com

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split

January 31, 2024 | msn.com

Werewolf Therapeutics Inc (HOWL)

January 31, 2024 | investing.com

Alaunos Therapeutics Inc [TCRT] Insider Boyle Kevin S. Sr. sells 68,014 Shares – Latest Insider Activity

January 3, 2024 | knoxdaily.com

Alaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and Dates

December 28, 2023 | benzinga.com

TCRT Shares Experience Decline in Value

November 17, 2023 | knoxdaily.com

Recap: Alaunos Therapeutics Q3 Earnings

November 14, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, TCRT, IMCC, and MBIO Company Descriptions

IM Cannabis NASDAQ:IMCC

$2.71 +0.84 (+44.92%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$2.74 +0.03 (+1.07%)

As of 05/28/2025 07:59 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Mustang Bio NASDAQ:MBIO

$1.28 -0.01 (-0.78%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.27 -0.01 (-0.39%)

As of 05/28/2025 07:37 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.52 +0.01 (+0.66%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.04 (-2.96%)

As of 05/28/2025 07:55 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Alaunos Therapeutics NASDAQ:TCRT

$2.48 -0.16 (-6.06%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$2.55 +0.07 (+2.78%)

As of 05/28/2025 05:35 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time